REGENXBIO, Inc. (RGNX)
8.075
-0.02
(-0.19%)
USD |
NASDAQ |
Oct 09, 16:00
8.075
0.00 (0.00%)
After-Hours: 18:23
REGENXBIO Enterprise Value : 582.91M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 582.91M |
| October 07, 2026 | 556.10M |
| October 06, 2026 | 548.24M |
| October 05, 2026 | 565.03M |
| October 02, 2026 | 547.16M |
| October 01, 2026 | 546.62M |
| September 30, 2026 | 552.57M |
| September 29, 2026 | 548.24M |
| September 28, 2026 | 549.33M |
| September 25, 2026 | 545.53M |
| September 24, 2026 | 536.87M |
| September 23, 2026 | 550.95M |
| September 22, 2026 | 586.16M |
| September 21, 2026 | 571.53M |
| September 18, 2026 | 579.66M |
| September 17, 2026 | 589.68M |
| September 16, 2026 | 576.95M |
| September 15, 2026 | 575.05M |
| September 14, 2026 | 615.41M |
| September 11, 2026 | 606.74M |
| September 10, 2026 | 608.36M |
| September 09, 2026 | 617.57M |
| September 08, 2026 | 619.20M |
| September 04, 2026 | 628.95M |
| September 03, 2026 | 643.03M |
| Date | Value |
|---|---|
| September 02, 2026 | 664.69M |
| September 01, 2026 | 649.53M |
| August 31, 2026 | 659.28M |
| August 28, 2026 | 667.94M |
| August 27, 2026 | 652.24M |
| August 26, 2026 | 652.78M |
| August 25, 2026 | 627.32M |
| August 24, 2026 | 581.01M |
| August 21, 2026 | 725.36M |
| August 20, 2026 | 743.77M |
| August 19, 2026 | 795.77M |
| August 18, 2026 | 744.32M |
| August 17, 2026 | 758.40M |
| August 14, 2026 | 727.80M |
| August 13, 2026 | 722.11M |
| August 12, 2026 | 735.65M |
| August 11, 2026 | 721.57M |
| August 10, 2026 | 709.11M |
| August 07, 2026 | 725.36M |
| August 06, 2026 | 755.69M |
| August 05, 2026 | 713.44M |
| August 04, 2026 | 702.61M |
| August 03, 2026 | 684.19M |
| July 31, 2026 | 669.57M |
| July 30, 2026 | 692.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 545.69B |
| United Therapeutics Corp. | 20.08B |
| Ardelyx, Inc. | 789.07M |
| Biomea Fusion, Inc. | 64.99M |
| RenovoRx, Inc. | 50.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 22.71M |
| Revenue (Quarterly) | 108.02M |
| Total Expenses (Quarterly) | 85.31M |
| EPS Diluted (Quarterly) | 0.4283 |
| Gross Profit Margin (Quarterly) | 95.56% |
| Profit Margin (Quarterly) | 21.02% |
| Earnings Yield | -46.87% |
| Normalized Earnings Yield | -46.87 |